They are specifically designed to reduce the incidence and severity of nausea, vomiting, and diarrhea during the early weeks of treatment
B12 deficiency can develop gradually and may present with a range of symptoms, some of which overlap with other conditions
availability has been significantly curtailed - No branded pharmaceutical product exists **Semaglutide:** - FDA-approved for weight management (Wegovy, 2.4 mg weekly) - FDA-approved for type 2 diabetes (Ozempic, up to 2.0 mg weekly) - Available through licensed pharmacies worldwide - Also available through 503B compounding pharmacies as a **weight loss peptide injection** - [View semaglutide products](/products/semaglutide-001) ### Injection Protocol Comparison **AOD-9604 typical research protocol:** - Dose: 250-300 mcg per injection - Frequency: Daily subcutaneous injection (fasting, typically morning) - Cycle length: 12-20 weeks - Total injections per month: ~30 **Semaglutide weight loss injection protocol:** - Starting dose: 0.25 mg weekly (4-week titration steps) - Maintenance dose: 2.4 mg weekly - Frequency: Once weekly subcutaneous injection - Total injections per month: 4 The convenience advantage is substantial
In the United States, the FDA did not approve the agent because of its association with a risk of psychiatric disorders including depression and suicidal tendencies [27]
Other contraindications and caution flags include Wilsons disease or another copper-handling disorder, pregnancy, recent surgery, and WADA-tested competition
